Horizon Discovery (Horizon) today announced it has signed a commercial agreement with Millennium Pharmaceuticals Incorporated to broadly evaluate its X-MAN™ technology.
X-MAN ‘Mutant And Normal’ human isogenic cell-lines are the first genetically-defined in vitro models of human cancer and their matched normal cell-types, that help accelerate and rationalize the discovery of novel ‘personalised’ medicines and their optimal assessment in clinical trials.
The agreement covers an eight month evaluation of a panel of seven X-MAN cell lines; including for the first time a set of double cancer-gene ‘knock-in’ lines designed to evaluate known mechanisms of patient resistance to targeted agents. The lines under evaluation represent model genotypes of interest to Millennium; who will further characterize the lines and test known targeted agents against these genotypes as well as internally developed compounds.
“Chris Torrance, CEO of Horizon says “it is our aim to get our novel ‘patient-relevant’ X-MAN cancer models rapidly into the real world drug discovery arena and signing up Millennium to a comprehensive and expandable pilot programme will generate additional data on the ability of X-MAN cell lines to find novel ‘personalised’ cancer therapies.”
Millennium will pay Horizon a six-figure fee and share key data-sets during the course of the evaluation period which will begin in October 2008.